… Please cite this paper as: Finkelsztejn A, Brooks J, Paschoal F, Fragoso Y. What can we
really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-…

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating central nervous system
disorder that is more common in women, with onset often during reproductive years. The …

Background: Interferon (IFN) beta is a safe and efficient drug for treating multiple sclerosis (MS).
It is widely accepted that previously depressed patients may get worse when using IFN-…

Multiple sclerosis is often diagnosed in patients who are planning on having children. Although
multiple sclerosis does not negatively influence most pregnancy outcomes, less is known …

BACKGROUND AND OBJECTIVE: Women with multiple sclerosis (MS) who intend to get
pregnant are often advised to discontinue disease modifying therapy (DMT) prior to conception…

Background: The risk factors for conversion from relapsing-remitting to secondary progressive
multiple sclerosis remain highly contested. Objective: The aim of this study was to …

Leflunomide modulates T-cell responses and induces a shift from the Th1 to Th2 subpopulation.
This process results in a beneficial effect in diseases in which there is good evidence …

Background: The MuSC-19 project is an Italian cohort study open to international partners
that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave …

Background: Glatiramer acetate is a US FDA category B drug with regard to use by
pregnant women with multiple sclerosis (MS). There are no data currently available for the …

… Dr Fragoso received honoraria as a consultant on scientific advisory boards by Novartis,
Teva, Roche, and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi …